ISCT NA 2023

Showcase your Research at the 
ISCT North America 2023 Regional Meeting 

With a truly translational focus, the ISCT NA 2023 Regional Meeting welcomes abstracts from basic science and preclinical studies, clinical investigations, manufacturing, regulatory, quality, policy, ethics, and commercialization. 

Your work is vital to advancing the field of cell and gene therapy. 

Submit your abstract(s) for the opportunity to be considered for an oral abstract or poster presentation to promote your work to key leaders in the CGT sector, gain exposure to potential collaborators and expand your professional network.  

Don't miss this opportunity to present your research with a community of experts across the translation field.  

Poster Specifications

Poster Dimensions are limited to 45” W x 40” H

Set-up and Tear Down

Poster presenters may set-up their posters beginning 07:00 Friday September 8
All posters must be torn down by 19:00 Saturday September 9
Posters remaining after this time will be removed and disposed of.  

Poster Networking Reception 1
September 8, 2023
18:30 - 20:00 

Poster Networking Reception 2
September 9, 2023
17:30 - 19:00 

Abstract Categories

  • Mesenchymal Stem/Stromal Cells
  • Hematopoietic Stem/Progenitor Cells and Engineering
  • Immunotherapy
  • Exosomes/EVs
  • iPSC
  • Gene Editing/Gene Therapy
  • Tissue Engineering
  • Embryonic, Organ and Other Tissue Specific Stem Cells
  • Process Development and Manufacturing
  • Regulatory Affairs, Quality Systems, Policy and Ethics
  • Workforce Development

Full List of Abstract Categories


  • Technologist Abstract Award ($500 USD)
  • Early Stage Professionals Abstract Award ($500 USD)

    Eligibility Criteria: Individuals must be presenting an abstract at ISCT NA 2023 and be a current ISCT member

    Guidelines and Policies

    • The abstract body cannot exceed 2500 characters, exclusive of the title, author block, images, and tables
    • Note that spaces count as characters
    • Abstracts must be submitted via the online Abstract Submission System. Abstracts will NOT be accepted by email, mail, or fax
    • ISCT may reject abstracts that are considered inappropriate for any reason. Abstracts, once submitted, can only be withdrawn no later than August 2, 2023. If not withdrawn by this deadline, All accepted abstracts will be published in the final program and abstract supplement
    • Abstract presenters MUST be registered for the meeting. For those requiring acceptance notifications before registering, ISCT NA 2023 will allow up to two weeks after acceptance for these individuals to register
    • Abstracts submitted to the ISCT North America 2023 Regional Meeting  are embargoed from the time of submission.
    • For the abstract to be eligible for presentation at the ISCT NA 2023 Regional Meeting, information contained within, as well as additional data and information to be presented about the content, may not be published elsewhere or made public before the abstract has been published/presented at the  ISCT NA 2023 Regional Meeting.
    • Authors must notify ISCT if, after the submission deadline, the submitted abstract is accepted for publication elsewhere and will be published before the ISCT North America 2023 Regional Meeting. Publication before the meeting may result in the abstract being removed from the conference.
    • If the Embargo Policy is violated, the abstract may be withdrawn by ISCT NA 2023 from presentation at the  ISCT North America 2023 Regional Meeting and from publication in the ISCT NA 2023 program.

    *An embargo means that information from any abstract or presentation may not be announced,
    publicized, or distributed before the embargo date and time.

    Avoidance of Marketing or Promotion
    ISCT requests that presenters avoid the use of trade names and logos for drugs, devices and/or instrumentation in these scientific sessions and to use generic names, where possible. Presentation content will be well-balanced, will be based on generally accepted scientific principles and methods, and will not promote a commercial interest.